Marshall Wace LLP Acquires 72,740 Shares of Fresenius Medical Care AG (NYSE:FMS)

Marshall Wace LLP boosted its stake in Fresenius Medical Care AG (NYSE:FMS - Free Report) by 128.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 129,581 shares of the company's stock after acquiring an additional 72,740 shares during the period. Marshall Wace LLP's holdings in Fresenius Medical Care were worth $2,934,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its stake in shares of Fresenius Medical Care by 192.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company's stock valued at $28,000 after purchasing an additional 806 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Fresenius Medical Care during the third quarter valued at $38,000. Russell Investments Group Ltd. boosted its holdings in shares of Fresenius Medical Care by 234.1% during the 4th quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company's stock valued at $71,000 after buying an additional 2,208 shares in the last quarter. Jones Financial Companies Lllp grew its position in shares of Fresenius Medical Care by 80.5% in the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company's stock worth $102,000 after buying an additional 2,012 shares during the period. Finally, Venturi Wealth Management LLC increased its stake in shares of Fresenius Medical Care by 8.4% in the 4th quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company's stock worth $129,000 after acquiring an additional 441 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. StockNews.com raised Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Truist Financial lifted their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the company a "hold" rating in a research note on Monday, January 6th.

Fresenius Medical Care Stock Up 2.4 %

Fresenius Medical Care stock traded up $0.61 during trading hours on Friday, hitting $25.63. The stock had a trading volume of 392,035 shares, compared to its average volume of 317,072. The stock's 50-day moving average price is $24.11 and its 200-day moving average price is $23.14. The stock has a market capitalization of $15.04 billion, a P/E ratio of 21.21, a price-to-earnings-growth ratio of 0.76 and a beta of 0.93. Fresenius Medical Care AG has a 12-month low of $17.93 and a 12-month high of $26.04. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.